NCT06517433 2024-07-24
First-in-Human Dose Escalation Study of XMT-1536 in Cancers Likely to Express NaPi2b
Mersana Therapeutics
Phase 1 Completed
Clinical Trials
3 trialsNCT06517485 2024-07-24
First-in-Human Dose Expansion Study of XMT-1536 in Cancers Likely to Express NaPi2b
Mersana Therapeutics
Phase 1 Completed
NCT01711970 2020-04-24
A Phase I/II Trial of VB-111 and Paclitaxel for Recurrent Platinum-Resistant Müllerian Cancer
Vascular Biogenics Ltd. operating as VBL Therapeutics
Phase 1/2 Completed